1921
Volume 88, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Controlled human malaria infection with sporozoites is a standardized and powerful tool for evaluation of malaria vaccine and drug efficacy but so far only applied by exposure to bites of (Pf)-infected mosquitoes. We assessed in an open label Phase 1 trial, infection after intradermal injection of respectively 2,500, 10,000, or 25,000 aseptic, purified, vialed, cryopreserved Pf sporozoites (PfSPZ) in three groups ( = 6/group) of healthy Dutch volunteers. Infection was safe and parasitemia developed in 15 of 18 volunteers (84%), 5 of 6 volunteers in each group. There were no differences between groups in time until parasitemia by microscopy or quantitative polymerase chain reaction, parasite kinetics, clinical symptoms, or laboratory values. This is the first successful infection by needle and syringe with PfSPZ manufactured in compliance with regulatory standards. After further optimization, the use of such PfSPZ may facilitate and accelerate clinical development of novel malaria drugs and vaccines.

[open-access] This is an Open Access article distributed under the terms of the American Society of Tropical Medicine and Hygiene's Re-use License which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2012.12-0613
2013-01-09
2017-09-26
Loading full text...

Full text loading...

/deliver/fulltext/14761645/88/1/5.html?itemId=/content/journals/10.4269/ajtmh.2012.12-0613&mimeType=html&fmt=ahah

References

  1. World Health Organization, Global Malaria Programme, 2010. World Malaria Report 2010: World Health Organization.
  2. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD, , 2012. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379: 413431.[Crossref]
  3. Alonso PL, Brown G, Arevalo-Herrera M, Binka F, Chitnis C, Collins F, Doumbo OK, Greenwood B, Hall BF, Levine MM, Mendis K, Newman RD, Plowe CV, Rodriguez MH, Sinden R, Slutsker L, Tanner M, , 2011. A research agenda to underpin malaria eradication. PLoS Med 8: e1000406.[Crossref]
  4. Najera JA, Gonzalez-Silva M, Alonso PL, , 2011. Some lessons for the future from the Global Malaria Eradication Programme (1955–1969). PLoS Med 8: e1000412.[Crossref]
  5. Sauerwein RW, Roestenberg M, Moorthy VS, , 2011. Experimental human challenge infections can accelerate clinical malaria vaccine development. Nat Rev Immunol 11: 5764.[Crossref]
  6. Covell G, Nicol WD, , 1951. Clinical, chemotherapeutic and immunological studies on induced malaria. Br Med Bull 8: 5155.[Crossref]
  7. Coggeshall LT, Craige B, Boyd MF, , 1949. Old and new plasmodicides. , ed. Malariology: A Comprehensive Survey of All Aspects of This Group of Diseases from a Global Standpoint. Philadelphia, PA: W. B. Saunders, 10711114.
  8. Alving AS, Arnold J, Hockwald RS, Clayman CB, Dern RJ, Beutler E, Flanagan CL, , 1955. Potentiation of the curative action of primaquine in vivax malaria by quinine and chloroquine. J Lab Clin Med 46: 301306.
  9. Shapiro TA, Ranasinha CD, Kumar N, Barditch-Crovo P, , 1999. Prophylactic activity of atovaquone against Plasmodium falciparum in humans. Am J Trop Med Hyg 60: 831836.
  10. Ifediba T, Vanderberg JP, , 1981. Complete in vitro maturation of Plasmodium falciparum gametocytes. Nature 294: 364366.[Crossref]
  11. Campbell CC, Collins WE, Nguyen Dinh P, Barber A, Broderson JR, , 1982. Plasmodium falciparum gametocytes from culture in vitro develop to sporozoites that are infectious to primates. Science 217: 10481050.[Crossref]
  12. Chulay JD, Schneider I, Cosgriff TM, Hoffman SL, Ballou WR, Quakyi IA, Carter R, Trosper JH, Hockmeyer WT, , 1986. Malaria transmitted to humans by mosquitoes infected from cultured Plasmodium falciparum . Am J Trop Med Hyg 35: 6668.
  13. Ballou WR, Hoffman SL, Sherwood JA, Hollingdale MR, Neva FA, Hockmeyer WT, Gordon DM, Schneider I, Wirtz RA, Young JF, Wasserman GF, Reeve P, Diggs CL, Chulay JD, , 1987. Safety and efficacy of a recombinant DNA Plasmodium falciparum sporozoite vaccine. Lancet 1: 12771281.[Crossref]
  14. Herrington DA, Clyde DF, Losonsky G, Cortesia M, Murphy JR, Davis J, Baqar S, Felix AM, Heimer EP, Gillessen D, Nardin E, Nussenzweig RS, Nussenzweig V, Hollingdale MR, Levine MM, , 1987. Safety and immunogenicity in man of a synthetic peptide malaria vaccine against Plasmodium falciparum sporozoites. Nature 328: 257259.[Crossref]
  15. Egan JE, Hoffman SL, Haynes JD, Sadoff JC, Schneider I, Grau GE, Hollingdale MR, Ballou WR, Gordon DM, , 1993. Humoral immune responses in volunteers immunized with irradiated Plasmodium falciparum sporozoites. Am J Trop Med Hyg 49: 166173.
  16. Hoffman SL, Edelman R, Bryan JP, Schneider I, Davis J, Sedegah M, Gordon D, Church P, Gross M, Silverman C, Hollingdale M, Clyde D, Sztein M, Losonsky G, Paparello S, Jones TR, , 1994. Safety, immunogenicity, and efficacy of a malaria sporozoite vaccine administered with monophosphoryl lipid A, cell wall skeleton of mycobacteria, and squalane as adjuvant. Am J Trop Med Hyg 51: 603612.
  17. Church LW, Le TP, Bryan JP, Gordon DM, Edelman R, Fries L, Davis JR, Herrington DA, Clyde DF, Shmuklarsky MJ, Schneider I, McGovern TW, Chulay JD, Ballou WR, Hoffman SL, , 1997. Clinical manifestations of Plasmodium falciparum malaria experimentally induced by mosquito challenge. J Infect Dis 175: 915920.[Crossref]
  18. Stoute JA, Slaoui M, Heppner DG, Momin P, Kester KE, Desmons P, Wellde BT, Garcon N, Krzych U, Marchand M, , 1997. A preliminary evaluation of a recombinant circumsporozoite protein vaccine against Plasmodium falciparum malaria. N Engl J Med 336: 8691.[Crossref]
  19. Epstein JE, Rao S, Williams F, Freilich D, Luke T, Sedegah M, de la Vega P, Sacci J, Richie TL, Hoffman SL, , 2007. Safety and clinical outcome of experimental challenge of human volunteers with Plasmodium falciparum-infected mosquitoes: an update. J Infect Dis 196: 145154.[Crossref]
  20. Thompson FM, Porter DW, Okitsu SL, Westerfeld N, Vogel D, Todryk S, Poulton I, Correa S, Hutchings C, Berthoud T, Dunachie S, Andrews L, Williams JL, Sinden R, Gilbert SC, Pluschke G, Zurbriggen R, Hill AV, , 2008. Evidence of blood stage efficacy with a virosomal malaria vaccine in a phase IIa clinical trial. PLoS ONE 3: e1493.[Crossref]
  21. Kester KE, Cummings JF, Ofori-Anyinam O, Ockenhouse CF, Krzych U, Moris P, Schwenk R, Nielsen RA, Debebe Z, Pinelis E, Juompan L, Williams J, Dowler M, Stewart J, Wirtz RA, Dubois MC, Lievens M, Cohen J, Ballou R, Heppner DG, Jr RTS,S Vaccine Evaluation Group; , 2009. Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S/AS01B and RTS,S/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection. J Infect Dis 200: 337346.[Crossref]
  22. Beadle C, Long GW, Weiss WR, McElroy PD, Maret SM, Oloo AJ, Hoffman SL, , 1994. Diagnosis of malaria by detection of Plasmodium falciparum HRP-2 antigen with a rapid dipstick antigen-capture assay. Lancet 343: 564568.[Crossref]
  23. McCall MB, Netea MG, Hermsen CC, Jansen T, Jacobs L, Golenbock D, van der Ven AJ, Sauerwein RW, , 2007. Plasmodium falciparum infection causes proinflammatory priming of human TLR responses. J Immunol 179: 162171.[Crossref]
  24. Clyde DF, Most H, McCarthy VC, Vanderberg JP, , 1973. Immunization of man against sporozoite-induced falciparum malaria. Am J Med Sci 266: 169177.[Crossref]
  25. Rieckmann KH, Carson PE, Beaudoin RL, Cassells JS, Sell KW, , 1974. Sporozoite induced immunity in man against an Ethiopian strain of Plasmodium falciparum . Trans R Soc Trop Med Hyg 68: 258259.[Crossref]
  26. Hoffman SL, Goh LM, Luke TC, Schneider I, Le TP, Doolan DL, Sacci J, de la Vega P, Dowler M, Paul C, Gordon DM, Stoute JA, Church LW, Sedegah M, Heppner DG, Ballou WR, Richie TL, , 2002. Protection of humans against malaria by immunization with radiation-attenuated Plasmodium falciparum sporozoites. J Infect Dis 185: 11551164.[Crossref]
  27. Roestenberg M, McCall M, Hopman J, Wiersma J, Luty AJ, van Gemert GJ, van de Vegte-Bolmer M, van Schaijk B, Teelen K, Arens T, Spaarman L, de Mast Q, Roeffen W, Snounou G, Renia L, van der Ven A, Hermsen CC, Sauerwein R, , 2009. Protection against a malaria challenge by sporozoite inoculation. N Engl J Med 361: 468477.[Crossref]
  28. Roestenberg M, Teirlinck AC, McCall MB, Teelen K, Makamdop KN, Wiersma J, Arens T, Beckers P, van Gemert G, van de Vegte-Bolmer M, van der Ven AJ, Luty AJ, Hermsen CC, Sauerwein RW, , 2011. Long-term protection against malaria after experimental sporozoite inoculation: an open-label follow-up study. Lancet 377: 17701776.[Crossref]
  29. James SP, Shute PG, , 1926. Report on the First Results of Laboratory Work on Malaria in England. Geneva: Publications of the League of Nations, Health Organization, 130.
  30. Maynes B, , 1933. The injection of mosquito sporozoites in malaria therapy. Public Health Rep 48: 909913.[Crossref]
  31. Mayne B, Young M, , 1941. The technique of induced malaria as used in the South Carolina State Hospital. J Vener Dis Inf 22: 271276.
  32. Jeffery GM, Rendtorff RC, , 1955. Preservation of viable human malaria sporozoites by low-temperature freezing. Exp Parasitol 4: 445454.[Crossref]
  33. Glynn JR, Bradley DJ, , 1995. Inoculum size, incubation period and severity of malaria. Analysis of data from malaria therapy records. Parasitology 110: 719.[Crossref]
  34. Hoffman SL, Billingsley PF, James E, Richman A, Loyevsky M, Li T, Chakravarty S, Gunasekera A, Li M, Stafford R, Ahumada A, Epstein JE, Sedegah M, Reyes S, Richie TL, Lyke KE, Edelman R, Laurens M, Plowe CV, Sim BK, , 2010. Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malaria. Hum Vaccin 6: 97106.[Crossref]
  35. Epstein JE, Tewari K, Lyke KE, Sim BK, Billingsley PF, Laurens MB, Gunasekera A, Chakravarty S, James ER, Sedegah M, Richman A, Velmurugan S, Reyes S, Li M, Tucker K, Ahumada A, Ruben AJ, Li T, Stafford R, Eappen AG, Tamminga C, Bennett JW, Ockenhouse CF, Murphy JR, Komisar J, Thomas N, Loyevsky M, Birkett A, Plowe CV, Loucq C, Edelman R, Richie TL, Seder RA, Hoffman SL, , 2011. Live attenuated malaria vaccine designed to protect through hepatic CD8+ T cell immunity. Science 334: 475480.[Crossref]
  36. Ponnudurai T, Lensen AH, Van Gemert GJ, Bensink MP, Bolmer M, Meuwissen JH, , 1989. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes. Parasitology 98: 165173.[Crossref]
  37. Holder AA, , 2009. The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology 136: 14451456.[Crossref]
  38. Sattabongkot J, Yimamnuaychoke N, Leelaudomlipi S, Rasameesoraj M, Jenwithisuk R, Coleman RE, Udomsangpetch R, Cui L, Brewer TG, , 2006. Establishment of a human hepatocyte line that supports in vitro development of the exo-erythrocytic stages of the malaria parasites Plasmodium falciparum and P. vivax . Am J Trop Med Hyg 74: 708715.
  39. Nieman AE, de Mast Q, Roestenberg M, Wiersma J, Pop G, Stalenhoef A, Druilhe P, Sauerwein R, van der Ven A, , 2009. Cardiac complication after experimental human malaria infection: a case report. Malar J 8: 277.[Crossref]
  40. de Mast Q, Groot E, Lenting PJ, de Groot PG, McCall M, Sauerwein RW, Fijnheer R, van der Ven A, , 2007. Thrombocytopenia and release of activated von Willebrand Factor during early Plasmodium falciparum malaria. J Infect Dis 196: 622628.[Crossref]
  41. Hermsen CC, Telgt DS, Linders EH, van de Locht LA, Eling WM, Mensink EJ, Sauerwein RW, , 2001. Detection of Plasmodium falciparum malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol 118: 247251.[Crossref]
  42. Roestenberg M, O'Hara GA, Duncan CJ, Epstein JE, Edwards NJ, Scholzen A, van der Ven AJ, Hermsen CC, Hill AV, Sauerwein RW, , 2012. Comparison of clinical and parasitological data from controlled human malaria infection trials. PLoS ONE 7: e38434.[Crossref]
  43. Verhage DF, Telgt DS, Bousema JT, Hermsen CC, van Gemert GJ, van der Meer JW, Sauerwein RW, , 2005. Clinical outcome of experimental human malaria induced by Plasmodium falciparum-infected mosquitoes. Neth J Med 63: 5258.
  44. Rickman LS, Jones TR, Long GW, Paparello S, Schneider I, Paul CF, Beaudoin RL, Hoffman SL, , 1990. Plasmodium falciparum-infected Anopheles stephensi inconsistently transmit malaria to humans. Am J Trop Med Hyg 43: 441445.
  45. Fries LF, Gordon DM, Schneider I, Beier JC, Long GW, Gross M, Que JU, Cryz SJ, Sadoff JC, , 1992. Safety, immunogenicity, and efficacy of a Plasmodium falciparum vaccine comprising a circumsporozoite protein repeat region peptide conjugated to Pseudomonas aeruginosa toxin A. Infect Immun 60: 18341839.
  46. WHO, 2011. Malaria Vaccine Rainbow Tables. Available at: http://www.who.int/vaccine_research/links/Rainbow/en/index.html. Accessed November 15, 2011.
  47. Hermsen CC, De Vlas SJ, van Gemert GJ, Telgt DS, Verhage DF, Sauerwein RW, , 2004. Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quantitative real-time polymerase chain reaction. Am J Trop Med Hyg 71: 196201.
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2012.12-0613
Loading
/content/journals/10.4269/ajtmh.2012.12-0613
Loading

Data & Media loading...

Supplementary Data

Supplementary PDF

  • Received : 03 Oct 2012
  • Accepted : 19 Oct 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error